AtriCure
ATRC
53.31
-0.37
-0.69%
AtriCure
US · ATRC
#2543 by market cap
Listed 1970
53.31
-0.37
-0.69%
Live - 5344 symbols - heartbeat 47s ago
· 2026-10-07 19:54
After-hours
53.31
0.00%
- Market cap
- 2.71B
- P/E (TTM)i
- 253.86
- P/Bi
- 5.25
- EPSi
- -0.24
- Div yieldi
- 0.00%
- 52W posi
- 77%
Reader sentiment
Are you bullish or bearish on ATRC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 10.36, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +14.88% YoY
Margins
- Gross margin
- 74.98%
- Operating margin
- -1.77%
- Net margin
- -2.14%
Key ratios & quality
- Altman Z-Scorei
- 10.36
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 201.63M | 230.81M | 206.53M | 274.33M | 330.38M | 399.25M | 465.31M | 534.53M |
| Gross profit | 147.12M | 170.34M | 149.31M | 205.86M | 245.94M | 300.37M | 347.52M | 400.78M |
| Selling & admin expenses | 129.52M | 167.14M | 150.83M | 204.65M | 231.27M | 253.14M | 291.36M | 311.02M |
| Research & development | 34.72M | 41.23M | 43.07M | 48.51M | 57.34M | 73.92M | 96.18M | 99.21M |
| Operating profit | -17.13M | -38.04M | -44.59M | -47.30M | -42.67M | -26.68M | -40.01M | -9.45M |
| Pretax profit | -20.91M | -35.00M | -48.04M | 50.39M | -46.20M | -29.85M | -43.67M | -10.16M |
| Tax | 226.00K | 199.00K | 114.00K | 188.00K | 268.00K | 591.00K | 1.02M | 1.29M |
| Net profit | -21.14M | -35.19M | -48.16M | 50.20M | -46.47M | -30.44M | -44.70M | -11.45M |
| Basic EPS | -1 | -1 | -1 | 1 | -1 | -1 | -1 | 0 |
| Diluted EPS | -0.62 | -0.94 | -1.14 | 1.09 | -1.02 | -0.66 | -0.95 | -0.24 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 123.62M | 136.14M | 134.27M | 140.50M | 141.25M | 153.60M |
| Gross profit | 92.63M | 101.48M | 101.33M | 105.34M | 109.31M | 118.63M |
| Selling & admin expenses | 76.05M | 78.39M | 78.23M | 78.34M | 84.55M | 82.56M |
| Research & development | 22.53M | 29.28M | 22.89M | 24.51M | 24.24M | 26.40M |
| Operating profit | -5.95M | -6.19M | 208.00K | 2.49M | 526.00K | 9.67M |
| Pretax profit | -6.51M | -5.93M | -86.00K | 2.36M | 394.00K | 9.43M |
| Tax | 239.00K | 261.00K | 181.00K | 604.00K | 286.00K | 471.00K |
| Net profit | -6.75M | -6.19M | -267.00K | 1.76M | 108.00K | 8.96M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.14 | -0.13 | -0.01 | 0.04 | 0.00 | 0.18 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 174.67M | 143.16M | 306.74M | 196.08M | 215.21M | 266.25M | 267.83M | 322.52M |
| Cash & ST investments | 124.40M | 81.80M | 244.22M | 119.09M | 121.11M | 137.29M | 122.72M | 167.43M |
| Inventory | 22.48M | 29.41M | 35.03M | 38.96M | 45.93M | 67.90M | 75.34M | 78.49M |
| Total assets | 356.76M | 557.88M | 714.54M | 615.31M | 585.45M | 613.93M | 609.33M | 654.18M |
| Total current liabilities | 40.22M | 49.92M | 49.14M | 56.45M | 58.39M | 74.57M | 73.42M | 81.52M |
| Short-term debt | 4.72M | 2.22M | 8.42M | -- | 5.47M | 2.53M | -- | -- |
| Long-term debt | 35.57M | 59.63M | 53.44M | 59.74M | 56.83M | 60.59M | 61.87M | 61.87M |
| Total liabilities | 107,378,000.00 | 310,537,000.00 | 302,145,000.00 | 131,556,000.00 | 128,694,000.00 | 147,764,000.00 | 148,359,000.00 | 162,244,000.00 |
| Total equity | 249.38M | 247.34M | 412.39M | 483.76M | 456.75M | 466.17M | 460.97M | 491.94M |
| Retained earnings | -247.00M | -282.20M | -330.35M | -280.15M | -326.62M | -357.06M | -401.76M | -413.20M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 251.48M | 271.26M | 301.11M | 322.52M | 313.69M | 345.53M |
| Cash & ST investments | 99.89M | 117.80M | 147.87M | 167.43M | 146.17M | 167.79M |
| Inventory | 74.91M | 76.34M | 78.95M | 78.49M | 81.14M | 83.93M |
| Total assets | 591.63M | 608.85M | 635.44M | 654.18M | 643.99M | 676.64M |
| Total current liabilities | 61.22M | 68.84M | 77.84M | 81.52M | 73.19M | 81.92M |
| Short-term debt | 2.84M | 2.91M | 3.00M | -- | -- | -- |
| Long-term debt | 61.87M | 61.87M | 61.87M | 61.87M | 61.00M | 61.00M |
| Total liabilities | 137,012,000.00 | 144,358,000.00 | 158,935,000.00 | 162,244,000.00 | 152,295,000.00 | 160,210,000.00 |
| Total equity | 454.62M | 464.49M | 476.51M | 491.94M | 491.69M | 516.43M |
| Retained earnings | -408.50M | -414.69M | -414.96M | -413.20M | -413.10M | -404.14M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -4.17M | -15.81M | -19.87M | -13.78M | -22.14M | 4.48M | 12.20M | 57.33M |
| Depreciation & amortization | 8.75M | 9.37M | 9.55M | 10.44M | 11.71M | 14.81M | 18.73M | 20.53M |
| Free cash flow | -10.38M | -27.99M | -25.13M | -23.53M | -39.02M | -37.51M | -11.26M | 42.28M |
| Dividends paid | -- | -- | -- | -- | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | 78.42M | -9.03M | 175.93M | -18.01M | -12.20M | -6.56M | -6.95M | -11.16M |
| Ending cash balance | 32.23M | 28.48M | 41.94M | 43.65M | 58.10M | 84.31M | 122.72M | 167.43M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -11.03M | 21.62M | 26.72M | 20.03M | -4.00M | 22.19M |
| Depreciation & amortization | 5.08M | 5.17M | 5.17M | 5.11M | 5.27M | 5.31M |
| Free cash flow | -13.21M | 13.96M | 24.11M | 17.43M | -7.85M | 18.43M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | -10.17M | -406.00K | -357.00K | -228.00K | -11.44M | -314.00K |
| Ending cash balance | 99.89M | 117.80M | 147.87M | 167.43M | 146.17M | 167.79M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -10.30 | -14.17 | -14.60 | 11.20 | -9.88 | -6.60 | -9.64 | -2.40 |
| ROA %i | -6.77 | -7.70 | -7.57 | 7.55 | -7.74 | -5.08 | -7.31 | -1.81 |
| ROIC %i | -7.40 | -10.85 | -11.21 | 10.45 | -8.17 | -5.26 | -8.02 | -1.89 |
| 5-year avg ROE %i | -15.65 | -15.32 | -14.83 | -8.84 | -7.55 | -6.81 | -5.90 | -3.46 |
| EBIT margin %i | -8.09 | -13.38 | -20.90 | 20.16 | -12.47 | -5.74 | -8.01 | -0.80 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 7.91 |
| Current ratioi | 4.34 | 2.87 | 6.24 | 3.47 | 3.69 | 3.57 | 3.65 | 3.96 |
| Quick ratioi | 3.72 | 2.20 | 5.44 | 2.69 | 2.81 | 2.55 | 2.49 | 2.87 |
| Debt / assetsi | 14.70 | 13.70 | 10.36 | 12.01 | 12.73 | 12.13 | 12.10 | 11.22 |
| LT debt / equityi | 19.14 | 30.00 | 15.90 | 15.27 | 15.12 | 15.44 | 15.99 | 14.92 |
| Interest coveragei | -3.54 | -7.51 | -8.83 | 11.25 | -8.27 | -3.31 | -5.82 | -0.73 |
| Revenue CAGR (3Y) %i | 15.83 | 14.17 | 5.73 | 10.81 | 12.70 | 24.57 | 19.26 | 17.40 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -8.38 | -7.85 | -6.11 | -2.40 | -0.97 | 2.15 |
| ROA %i | -6.45 | -6.03 | -4.60 | -1.81 | -0.74 | 1.64 |
| ROIC %i | -6.95 | -6.52 | -5.05 | -1.89 | -0.72 | 1.98 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -6.45 | -5.85 | -4.24 | -0.80 | 0.46 | 3.11 |
| FCF / sales %i | -- | 1.66 | 3.09 | 7.91 | 8.63 | 9.15 |
| Current ratioi | 4.11 | 3.94 | 3.87 | 3.96 | 4.29 | 4.22 |
| Quick ratioi | 2.67 | 2.67 | 2.71 | 2.87 | 2.97 | 3.02 |
| Debt / assetsi | 13.08 | 12.69 | 12.08 | 11.22 | 11.15 | 10.50 |
| LT debt / equityi | 16.40 | 16.01 | 15.47 | 14.92 | 14.60 | 13.76 |
| Interest coveragei | -5.04 | -4.85 | -3.78 | -0.73 | 0.44 | 3.15 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Appendage management is the largest reported line at 41.66% of revenue, across 4 reported segments.
- No single line clears half of revenue; Open ablation is next at 33.94%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Appendage management41.66%
Open ablation33.94%
Pain management19.16%
Minimally invasive ablation5.24%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.